Sign in Join
Daily desk

News

Artificial intelligence, technology, science, health and education — reported daily, with the original source attached to every item.

Topic All 🤖 Artificial Intelligence ⚡ Technology 🔭 Science 🩺 Health 🎓 Education 🌱 Climate & Energy 🚀 Space 📈 Policy & Business Sort Clear

1 item(s)

A bispecific antibody schematic bridges a T-cell and a myeloma cell, alongside headline stats showing 77.8% complete response, 92% two-year progression-free survival, and a hazard ratio of 0.15 for teclistamab.
🩺 Health Study

Randomized Trial Finds Teclistamab Outperforms Standard Early Treatment in High-Risk Smoldering Myeloma

A phase 2 trial in Nature Medicine found that early teclistamab treatment produced deep, durable remissions in high-risk smoldering myeloma…

Mustafa Pat · 2h ago · 4 min read